{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:44:33Z","timestamp":1751053473609,"version":"3.41.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[1997,7]]},"DOI":"10.1023\/a:1007761825414","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T11:08:11Z","timestamp":1040555291000},"page":"499-508","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Almokalant, a Class III Antiarrhythmic Agent, on Supraventricular, Reentrant Tachycardias"],"prefix":"10.1007","volume":"11","author":[{"given":"B\u00f6rje","family":"Darp\u00f6","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Edvardsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"145429_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cvr\/26.11.1145","volume":"26","author":"E Wettwer","year":"1992","unstructured":"Wettwer E, Grundke M, Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovase Res 1992;26:1\u20138.","journal-title":"Cardiovase Res"},{"key":"145429_CR2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.RES.73.5.857","volume":"73","author":"E. Carmeliet","year":"1993","unstructured":"Carmeliet E. Use-dependent block and use-dependent unblock of the delayed K+ current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857\u2013868.","journal-title":"Circ Res"},{"key":"145429_CR3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00005344-199209000-00018","volume":"20","author":"G Duker","year":"1992","unstructured":"Duker G, Almgren O, Carlsson L. Electrophysiologic and hemodynamic effects of H234\/09 (almokalant), quinidine, and (+)-sotalol in the anaesthetized dog. J Cardiovasc Pharmacol 1992;20:458\u2013465.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/00005344-199112000-00015","volume":"18","author":"L Carlsson","year":"1991","unstructured":"Carlsson L, Abrahamsson C, Almgren O, Lundberg C, Duker G. Prolonged action potential duration and positive inotropy induced by the novel class III antiarrhythmic agent H234\/09 (almokalant) in isolated human ventricular muscle. J Cardiovasc Pharmacol 1991;18:882\u2013887.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/cvr\/27.5.861","volume":"27","author":"C Abrahamsson","year":"1993","unstructured":"Abrahamsson C, Duker G, Lundberg C, Carlsson L. Electrophysiological and inotropic effects of H234\/09 (almokalant) in vitro: A comparison with two other novel Ik blocking drugs, UK-68,789 (dofetilide) and E-4031. Cardiovasc Res 1993;27:861\u2013867.","journal-title":"Cardiovasc Res"},{"key":"145429_CR6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00005344-199505000-00001","volume":"25","author":"B Darp\u00f6","year":"1995","unstructured":"Darp\u00f6 B, Almgren O, Bergstrand R, et al. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and AV nodal function in the heart. J Cardiovasc Pharmacol 1995;25:681\u2013690.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00005344-199510000-00005","volume":"26","author":"B Darp\u00f6","year":"1995","unstructured":"Darp\u00f6 B, Vallin H, Almgren O, Bergstrand R, Insulander P, Edvardsson N. The selective Ik blocker almokalant exhibits class III specific effects on repolarization and refractoriness of the human heart. J Cardiovasc Pharmacol 1995;26:530\u2013540.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF00050994","volume":"10","author":"B Darp\u00f6","year":"1996","unstructured":"Darp\u00f6 B, Almgren O, Bergstrand R, Franz\u00e9n S, Edvardsson N. Assessment of frequency-dependency of the class III effects of almokalant. A study using programmed stimulation and recordings of monophasic action potentials and ventricular paced QT-intervals. Cardiovasc Drug Therapy 1996;10:539\u2013547.","journal-title":"Cardiovasc Drug Therapy"},{"key":"145429_CR9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/0002-9149(92)90349-4","volume":"70","author":"A Wiesfeld","year":"1992","unstructured":"Wiesfeld A, Crijns H, Tob\u00e9 T, et al. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Am J Cardiol 1992;70:990\u2013996.","journal-title":"Am J Cardiol"},{"key":"145429_CR10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00005344-199508000-00004","volume":"26","author":"B Darp\u00f6","year":"1995","unstructured":"Darp\u00f6 B, Edvardsson N for the Almokalant PSVT Study Group. The efficacy of almokalant, a selective Ik blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias. J Cardiovasc Pharmacol 1995;26:198\u2013206.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR11","first-page":"353","volume":"7","author":"HC. Bazett","year":"1920","unstructured":"Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353\u2013369.","journal-title":"Heart"},{"key":"145429_CR12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/01.CIR.65.2.336","volume":"65","author":"JJ Gallagher","year":"1982","unstructured":"Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: A diagnostic and therapeutic tool. Circulation 1982;65:336\u2013341.","journal-title":"Circulation"},{"key":"145429_CR13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0002-9149(90)90296-D","volume":"65","author":"B Brembilla-Perrot","year":"1990","unstructured":"Brembilla-Perrot B, Spatz F, Khaldi E, Terrier de la Chaise A, Le Van D, Pernot C. Value of esophageal pacing in evaluation of supraventricular tachycardias. Am J Cardiol 1990;65:322\u2013330.","journal-title":"Am J Cardiol"},{"key":"145429_CR14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/01.CIR.66.1.196","volume":"66","author":"CR Kerr","year":"1982","unstructured":"Kerr CR, Gallagher JJ, German LD. Changes in ventriculoatrial intervals with bundle branch block aberration during reentrant tachycardia in patients with accessory atrioventricular pathways. Circulation 1982;66:196\u2013201.","journal-title":"Circulation"},{"key":"145429_CR15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.CIR.75.5.1050","volume":"75","author":"K Kunze","year":"1987","unstructured":"Kunze K, Schl\u00fcter M, Kuck KH. Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987;75:1050\u20131057.","journal-title":"Circulation"},{"key":"145429_CR16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.CIR.69.1.120","volume":"69","author":"H Wellens","year":"1984","unstructured":"Wellens H, Brugada P, Abdollah H, Dassen W. A comparison of the electrophysiological effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69:120\u2013124.","journal-title":"Circulation"},{"key":"145429_CR17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00005344-199423030-00003","volume":"23","author":"A Fujiki","year":"1994","unstructured":"Fujiki A, Tani M, Mizumaki K, Shimono M, Inoue H. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1994;23:374\u2013378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0002-9149(78)90858-5","volume":"41","author":"P Denes","year":"1978","unstructured":"Denes P, Cummings JM, Simpson R, et al. Effects of propranolol on anomalous pathway refractoriness and circus movement tachycardias in patients with preexcitation. Am J Cardiol 1978;41:1061\u20131067.","journal-title":"Am J Cardiol"},{"key":"145429_CR19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00005344-198201000-00003","volume":"4","author":"R Gmeiner","year":"1982","unstructured":"Gmeiner R, Ng CK. Metoprolol in the treatment and prophylaxis of paroxysmal reentrant supraventricular tachycardia. J Cardiovasc Pharmacol 1982;4:5\u201313.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/01.CIR.75.5.930","volume":"75","author":"JM Miller","year":"1987","unstructured":"Miller JM, Rosenthal ME, Vasallo JA, Josephson M. Atrioventricular nodal reentrant tachycardia: Studies on upper and lower common pathways. Circulation 1987;75:930\u2013940.","journal-title":"Circulation"},{"key":"145429_CR21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0002-9149(84)90189-9","volume":"54","author":"DA Chilson","year":"1984","unstructured":"Chilson DA, Zipes DP, Heger JJ, Browne KF, Prystowsky EN. Functional bundle branch block: Discordant response of right and left bundle branches to changes in heart rate. Am J Cardiol 1984;54;313\u2013316.","journal-title":"Am J Cardiol"},{"key":"145429_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1172\/JCI112138","volume":"76","author":"MH Lehmann","year":"1985","unstructured":"Lehmann MH, Denker S, Mahmud R, Tchou P, Dongas J, Akhtar M. Electrophysiological mechanisms of functional bundle branch block at onset of induced orthodromic tachycardia in the Wolff-Parkinson-White syndrome: Role of stimulation method. J Clin Invest 1985;76;66\u20131574.","journal-title":"J Clin Invest"},{"key":"145429_CR23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1540-8159.1993.tb04575.x","volume":"16","author":"H Crijns","year":"1993","unstructured":"Crijns H, Kingma H, Gosselink M, Lie K. Comparison in the same patient of abberrant conduction and bundle branch reentrant after dofetilide, a new selective class III antiarrhythmic agent. Pace 1993;16:1006\u20131016.","journal-title":"Pace"},{"key":"145429_CR24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.CIR.81.2.686","volume":"81","author":"LM Hondeghem","year":"1990","unstructured":"Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686\u2013690.","journal-title":"Circulation"},{"key":"145429_CR25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1540-8167.1990.tb01059.x","volume":"1","author":"W. Jackman","year":"1990","unstructured":"Jackman W. Szabo B, Friday K, et al. Ventricular tachyarrhythmias related to early afterdepolarizations and triggered firing: Relationship to QT interval prolongation and potential therapeutic role of calcium channel blocking agents. J Cardiovasc Electrophysiol 1990;1:170\u2013195.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"145429_CR26","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0002-8703(87)90664-8","volume":"113","author":"HG Startmann","year":"1987","unstructured":"Startmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins. Recognition and management. Am Heart J 1987;113:1470\u20131482.","journal-title":"Am Heart J"},{"key":"145429_CR27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199008000-00014","volume":"16","author":"L Carlsson","year":"1990","unstructured":"Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit. Etiology and interventions. J Cardiovasc Pharmacol 1990;16:276\u2013285.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1527-3466.1996.tb00314.x","volume":"14","author":"B Darp\u00f6","year":"1996","unstructured":"Darp\u00f6 B, Almgren O. Almokalant\u2014a selective class III antiarrhythmic compound. Cardiovasc Drug Rev 1996;14:60\u201383.","journal-title":"Cardiovasc Drug Rev"},{"key":"145429_CR29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1527-3466.1992.tb00245.x","volume":"10","author":"TM. Argentieri","year":"1992","unstructured":"Argentieri TM. Sematilide. Cardiovasc Drug Rev 1992;10:182\u2013198.","journal-title":"Cardiovasc Drug Rev"},{"issue":"Suppl2","key":"145429_CR30","first-page":"96P","volume":"20","author":"HS Rasmussen","year":"1992","unstructured":"Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW. Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992;20(Suppl 2):96P\u2013105P.","journal-title":"J Cardiovasc Pharmacol"},{"key":"145429_CR31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0167-5273(95)02284-4","volume":"49","author":"ML Sedgwick","year":"1995","unstructured":"Sedgwick ML, Lip G, Rae AP, Cobbe S. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995;49:159\u2013166.","journal-title":"Int J Cardiol"},{"key":"145429_CR32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-5273(95)02540-5","volume":"53","author":"B Darp\u00f6","year":"1996","unstructured":"Darp\u00f6 B, Allared M, Edvardsson N. Torsades de pointes induced by transesophageal atrial stimulation after administration of almokalant. Int J Cardiol 1996;53:311\u2013313.","journal-title":"Int J Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1007761825414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1007761825414\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1007761825414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:12:06Z","timestamp":1751051526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1007761825414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["145429"],"URL":"https:\/\/doi.org\/10.1023\/a:1007761825414","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}